{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:55:09Z","timestamp":1787241309211,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03351-1","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:55:59Z","timestamp":1743818159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spatial and functional profiles distinguish target sets of Parkinson\u2019s disease and antipsychotic drugs with different clinical effects"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-7750","authenticated-orcid":false,"given":"Kalyani B.","family":"Karunakaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-130X","authenticated-orcid":false,"given":"Darius","family":"Widera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme S.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"3351_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson\u2019s disease. Drugs Aging. 2008;25:665\u201382.","journal-title":"Drugs Aging"},{"key":"3351_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1345\/aph.1M183","volume":"43","author":"SC Stoner","year":"2009","unstructured":"Stoner SC, Dahmen MM, Makos M, Lea JW, Carver LJ, Rasu RS. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson\u2019s disease. Ann Pharmacother. 2009;43:1426\u201332.","journal-title":"Ann Pharmacother"},{"key":"3351_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2021.07.026","volume":"90","author":"KA Sakhardande","year":"2021","unstructured":"Sakhardande KA, Reddi VSK, Mishra S, Navin K, Ramu A, Arunachal G, et al. Homozygous PLA2G6 (PARK 14) gene mutation associated neuropsychiatric phenotypes from southern India. Parkinsonism Relat Disord. 2021;90:49\u201351.","journal-title":"Parkinsonism Relat Disord"},{"key":"3351_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"H-W Shin","year":"2012","unstructured":"Shin H-W, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15\u201321.","journal-title":"J Clin Neurol"},{"key":"3351_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/mds.10362","volume":"18","author":"J Benito\u2010Le\u00f3n","year":"2003","unstructured":"Benito\u2010Le\u00f3n J, Bermejo\u2010Pareja F, Rodr\u00edguez J, Molina JA, Gabriel R, Morales JM, Group NDiCSS. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18:267\u201374.","journal-title":"Mov Disord"},{"key":"3351_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161:160\u20133.","journal-title":"Am J Psychiatry"},{"key":"3351_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","volume":"172","author":"T Kuroki","year":"2008","unstructured":"Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin\u2013dopamine hypothesis. Prog Brain Res. 2008;172:199\u2013212.","journal-title":"Prog Brain Res"},{"key":"3351_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4088\/JCP.v62n1001","volume":"62","author":"SM Stahl","year":"2001","unstructured":"Stahl SM. \u201cHit-and-Run\u201d actions at dopamine receptors, part 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiatry. 2001;62:747\u20138.","journal-title":"J Clin Psychiatry"},{"key":"3351_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Group PS.","year":"1999","unstructured":"Group PS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"3351_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/PL00007823","volume":"248","author":"S Kuzuhara","year":"2001","unstructured":"Kuzuhara S. Drug-induced psychotic symptoms in Parkinson\u2019s disease. Problems, management and dilemma. J Neurol. 2001;248:28\u201331.","journal-title":"J Neurol"},{"key":"3351_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon G, Mahieux F, Huon R, Zi\u00e9gler M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733\u201345.","journal-title":"Brain"},{"key":"3351_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80765-5","volume":"11","author":"CR Oehrn","year":"2021","unstructured":"Oehrn CR, Sch\u00f6nenkorb J, Timmermann L, Nenadi\u0107 I, Weber I, Grant P. Schizotypy in Parkinson\u2019s disease predicts dopamine-associated psychosis. Sci Rep. 2021;11:759.","journal-title":"Sci Rep"},{"key":"3351_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fpsyt.2014.00184","volume":"5","author":"C Mohr","year":"2014","unstructured":"Mohr C, Ettinger U. An overview of the association between schizotypy and dopamine. Front Psychiatry. 2014;5:184.","journal-title":"Front Psychiatry"},{"key":"3351_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4103\/IJPSYM.IJPSYM_68_17","volume":"39","author":"S Grover","year":"2017","unstructured":"Grover S, Sahoo S, Goyal MK. Schizophrenia with comorbid idiopathic Parkinson\u2019s disease: a difficult clinical management scenario. Indian J Psychol Med. 2017;39:823\u20137.","journal-title":"Indian J Psychol Med"},{"key":"3351_CR15","first-page":"179","volume":"14","author":"S Sharma","year":"2019","unstructured":"Sharma S, Aggarwal N. Idiopathic Parkinson\u2019s disease and schizophrenia: dilemma in diagnosis and treatment of a case. Iran J Psychiatry. 2019;14:179.","journal-title":"Iran J Psychiatry"},{"key":"3351_CR16","first-page":"139","volume":"22","author":"J Oh","year":"2017","unstructured":"Oh J, Shen G, Nan G, Kim J-M, Jung K-Y, Jeon B. Comorbid schizophrenia and Parkinson\u2019s disease: a case series and brief review. Neurol Asia. 2017;22:139\u201342.","journal-title":"Neurol Asia"},{"key":"3351_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/00006231-200107000-00016","volume":"22","author":"L Pilowsky","year":"2001","unstructured":"Pilowsky L. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl Med Commun. 2001;22:829\u201333.","journal-title":"Nucl Med Commun"},{"key":"3351_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/bjp.179.6.503","volume":"179","author":"X Xiberas","year":"2001","unstructured":"Xiberas X, Martinot J, Mallet L, Artiges E, Loc\u2019h C, Maziere B, et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001;179:503\u20138.","journal-title":"Br J Psychiatry"},{"key":"3351_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004714-200104000-00013","volume":"21","author":"X Xiberas","year":"2001","unstructured":"Xiberas X, Martinot J-L, Mallet L, Artiges E, Canal M, Loc\u2019h C, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol. 2001;21:207\u201314.","journal-title":"J Clin Psychopharmacol"},{"key":"3351_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.nicl.2017.09.004","volume":"16","author":"B Ng","year":"2017","unstructured":"Ng B, Varoquaux G, Poline JB, Thirion B, Greicius MD, Poston KL. Distinct alterations in Parkinson\u2019s medication-state and disease-state connectivity. Neuroimage Clin. 2017;16:575\u201385.","journal-title":"Neuroimage Clin"},{"key":"3351_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnagi.2020.00075","volume":"12","author":"C Yang","year":"2020","unstructured":"Yang C, Zhang T, Wang W, Xiang Y, Huang Q, Xie C, et al. Brain-region specific metabolic abnormalities in Parkinson\u2019s disease and levodopa-induced dyskinesia. Front Aging Neurosci. 2020;12:75.","journal-title":"Front Aging Neurosci"},{"key":"3351_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","volume":"69","author":"I Kusumi","year":"2015","unstructured":"Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015;69:243\u201358.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3351_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/pcn.12938","volume":"74","author":"M Subbanna","year":"2020","unstructured":"Subbanna M, Shivakumar V, Venugopal D, Narayanaswamy JC, Berk M, Varambally S, et al. Impact of antipsychotic medication on IL\u20106\/stat3 signaling axis in peripheral blood mononuclear cells of drug\u2010naive schizophrenia patients. Psychiatry Clin Neurosci. 2020;74:64\u201369.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3351_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgab012","volume":"2","author":"M Leboyer","year":"2021","unstructured":"Leboyer M, Godin O, Terro E, Boukouaci W, Lu C-l, Andre M, et al. Immune signatures of treatment-resistant schizophrenia: a fondamental academic centers of expertise for schizophrenia (FACE-SZ) study. Schizophr Bull Open. 2021;2:sgab012.","journal-title":"Schizophr Bull Open"},{"key":"3351_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/schbul\/sbab092","volume":"48","author":"IA Akkouh","year":"2022","unstructured":"Akkouh IA, Hribkova H, Grabiec M, Budinska E, Szabo A, Kasparek T, et al. Derivation and molecular characterization of a morphological subpopulation of human ipsc astrocytes reveal a potential role in schizophrenia and clozapine response. Schizophr Bull. 2022;48:190\u20138.","journal-title":"Schizophr Bull"},{"key":"3351_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102206","volume":"71","author":"I Barrio-Hernandez","year":"2022","unstructured":"Barrio-Hernandez I, Beltrao P. Network analysis of genome-wide association studies for drug target prioritisation. Curr Opin Chem Biol. 2022;71:102206.","journal-title":"Curr Opin Chem Biol"},{"key":"3351_CR27","doi-asserted-by":"publisher","first-page":"100341","DOI":"10.1016\/j.xgen.2023.100341","volume":"3","author":"MC Sadler","year":"2023","unstructured":"Sadler MC, Auwerx C, Deelen P, Kutalik Z. Multi-layered genetic approaches to identify approved drug targets. Cell Genom. 2023;3:100341.","journal-title":"Cell Genom"},{"key":"3351_CR28","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901\u2013D906.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR29","doi-asserted-by":"publisher","first-page":"125ra131","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Patrick PY, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125ra131.","journal-title":"Sci Transl Med"},{"key":"3351_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nmeth.2689","volume":"10","author":"M Griffith","year":"2013","unstructured":"Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, et al. DGIdb: mining the druggable genome. Nat Methods. 2013;10:1209\u201310.","journal-title":"Nat Methods"},{"key":"3351_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","volume":"489","author":"MJ Hawrylycz","year":"2012","unstructured":"Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391.","journal-title":"Nature"},{"key":"3351_CR32","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43:W566\u201370.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR33","first-page":"30602","volume-title":"Principal components analysis (PCA)","author":"SM Holland","year":"2008","unstructured":"Holland SM. Principal components analysis (PCA). Athens, GA: Department of Geology, University of Georgia; 2008. p. 30602\u20132501."},{"key":"3351_CR34","doi-asserted-by":"publisher","first-page":"D996","DOI":"10.1093\/nar\/gks1042","volume":"41","author":"SM Sunkin","year":"2012","unstructured":"Sunkin SM, Ng L, Lau C, Dolbeare T, Gilbert TL, Thompson CL, et al. Allen brain atlas: an integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 2012;41:D996\u20131008.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"G Consortium","year":"2015","unstructured":"Consortium G. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648\u201360.","journal-title":"Science"},{"key":"3351_CR36","first-page":"227","volume":"27","author":"JM Palacios","year":"1988","unstructured":"Palacios JM, Camps M, Cortes R, Probst A. Mapping dopamine receptors in the human brain. J Neural Transm Suppl. 1988;27:227\u201335.","journal-title":"J Neural Transm Suppl"},{"key":"3351_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjschz.2016.12","volume":"2","author":"MK Ganapathiraju","year":"2016","unstructured":"Ganapathiraju MK, Thahir M, Handen A, Sarkar SN, Sweet RA, Nimgaonkar VL, et al. Schizophrenia interactome with 504 novel protein\u2013protein interactions. NPJ Schizophr. 2016;2:1\u201310.","journal-title":"NPJ Schizophr"},{"key":"3351_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.cell.2006.03.032","volume":"125","author":"J Lim","year":"2006","unstructured":"Lim J, Hao T, Shaw C, Patel AJ, Szab\u00f3 G, Rual J-F, et al. A protein\u2013protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell. 2006;125:801\u201314.","journal-title":"Cell"},{"key":"3351_CR39","doi-asserted-by":"publisher","first-page":"86ra49","DOI":"10.1126\/scitranslmed.3002166","volume":"3","author":"Y Sakai","year":"2011","unstructured":"Sakai Y, Shaw CA, Dawson BC, Dugas DV, Al-Mohtaseb Z, Hill DE, et al. Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med. 2011;3:86ra49.","journal-title":"Sci Transl Med"},{"key":"3351_CR40","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49:D605\u201312.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","volume":"82","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Henricks AM, Sullivan ED, Green AI. Unique effects of clozapine: a pharmacological perspective. Adv Pharmacol. 2018;82:137\u201362.","journal-title":"Adv Pharmacol"},{"key":"3351_CR42","doi-asserted-by":"crossref","unstructured":"Pi\u00f1ero J, Bravo \u00c0, Queralt-Rosinach N, Guti\u00e9rrez-Sacrist\u00e1n A, Deu-Pons J, Centeno E et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic acids research 2016;45:gkw943.","DOI":"10.1093\/nar\/gkw943"},{"key":"3351_CR43","doi-asserted-by":"publisher","first-page":"D535","DOI":"10.1093\/nar\/gkj109","volume":"34","author":"C Stark","year":"2006","unstructured":"Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006;34:D535\u2013D539.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR44","doi-asserted-by":"publisher","first-page":"D767","DOI":"10.1093\/nar\/gkn892","volume":"37","author":"T Keshava Prasad","year":"2009","unstructured":"Keshava Prasad T, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human protein reference database\u20142009 update. Nucleic Acids Res. 2009;37:D767\u2013D772.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR45","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g: Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191\u2013W198.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR46","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1073\/pnas.1201547109","volume":"109","author":"P Hashemi","year":"2012","unstructured":"Hashemi P, Dankoski EC, Lama R, Wood KM, Takmakov P, Wightman RM. Brain dopamine and serotonin differ in regulation and its consequences. Proc Natl Acad Sci USA. 2012;109:11510\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3351_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.153.4.466","volume":"153","author":"S Kapur","year":"1996","unstructured":"Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466\u201376.","journal-title":"Am J Psychiatry"},{"key":"3351_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnmol.2018.00040","volume":"11","author":"M Szlachta","year":"2018","unstructured":"Szlachta M, Ku\u015bmider M, Pabian P, Solich J, Kolasa M, \u017burawek D, et al. Repeated clozapine increases the level of serotonin 5-HT1AR heterodimerization with 5-HT2A or dopamine D2 receptors in the mouse cortex. Front Mol Neurosci. 2018;11:40.","journal-title":"Front Mol Neurosci"},{"key":"3351_CR49","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983","volume":"3","author":"LA Chiodo","year":"1983","unstructured":"Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607\u201319.","journal-title":"J Neurosci"},{"key":"3351_CR50","doi-asserted-by":"publisher","first-page":"12330","DOI":"10.1523\/JNEUROSCI.2808-11.2011","volume":"31","author":"O Valenti","year":"2011","unstructured":"Valenti O, Cifelli P, Gill KM, Grace AA. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci. 2011;31:12330\u20138.","journal-title":"J Neurosci"},{"key":"3351_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.brainres.2010.04.083","volume":"1343","author":"J Tang","year":"2010","unstructured":"Tang J, Liao Y, Zhou B, Tan C, Liu T, Hao W, et al. Abnormal anterior cingulum integrity in first episode, early-onset schizophrenia: a diffusion tensor imaging study. Brain Res. 2010;1343:199\u2013205.","journal-title":"Brain Res"},{"key":"3351_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nicl.2014.06.003","volume":"5","author":"TJ Whitford","year":"2014","unstructured":"Whitford TJ, Lee SW, Oh JS, de Luis-Garcia R, Savadjiev P, Alvarado JL, et al. Localized abnormalities in the cingulum bundle in patients with schizophrenia: a diffusion tensor tractography study. Neuroimage Clin. 2014;5:93\u201399.","journal-title":"Neuroimage Clin"},{"key":"3351_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4103\/ijmr.IJMR_2556_19","volume":"156","author":"N Chawla","year":"2022","unstructured":"Chawla N, Deep R, Khandelwal SK, Garg A. Cingulum bundle integrity in schizophrenia with auditory verbal hallucinations: a diffusion tensor imaging tractographic study. Indian J Med Res. 2022;156:535.","journal-title":"Indian J Med Res"},{"key":"3351_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.mp.4002064","volume":"13","author":"L Xiao","year":"2008","unstructured":"Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry. 2008;13:697\u2013708.","journal-title":"Mol Psychiatry"},{"key":"3351_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2012.04.006","volume":"138","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhang H, Wang L, Jiang W, Xu H, Xiao L, et al. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res. 2012;138:8\u201317.","journal-title":"Schizophr Res"},{"key":"3351_CR56","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.biopsych.2007.08.018","volume":"63","author":"GT Konopaske","year":"2008","unstructured":"Konopaske GT, Dorph-Petersen K-A, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008;63:759\u201365.","journal-title":"Biol Psychiatry"},{"key":"3351_CR57","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms18081689","volume":"18","author":"AC Yang","year":"2017","unstructured":"Yang AC, Tsai S-J. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017;18:1689.","journal-title":"Int J Mol Sci"},{"key":"3351_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0074-7742(06)78007-2","volume":"78","author":"JA Berman","year":"2007","unstructured":"Berman JA, Talmage DA, Role LW. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol. 2007;78:193\u2013223.","journal-title":"Int Rev Neurobiol"},{"key":"3351_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fpsyt.2013.00045","volume":"4","author":"R Nieto","year":"2013","unstructured":"Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry. 2013;4:45.","journal-title":"Front Psychiatry"},{"key":"3351_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10565-008-9086-6","volume":"25","author":"T Cornetta","year":"2009","unstructured":"Cornetta T, Palma S, Aprile I, Padua L, Tonali P, Testa A, et al. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson\u2019s disease. Cell Biol Toxicol. 2009;25:321\u201330.","journal-title":"Cell Biol Toxicol"},{"key":"3351_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"A-L Barab\u00e1si","year":"2011","unstructured":"Barab\u00e1si A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56\u201368.","journal-title":"Nat Rev Genet"},{"key":"3351_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","volume":"192","author":"S Aringhieri","year":"2018","unstructured":"Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20\u201341.","journal-title":"Pharmacol Ther"},{"key":"3351_CR63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414\u201325.","journal-title":"Am J Psychiatry"},{"key":"3351_CR64","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371\u20136.","journal-title":"BMJ"},{"key":"3351_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","volume":"7","author":"A-M Bagnall","year":"2003","unstructured":"Bagnall A-M, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess (Rockv). 2003;7:1\u2013193.","journal-title":"Health Technol Assess (Rockv)"},{"key":"3351_CR66","first-page":"9","volume":"65","author":"G Chouinard","year":"2004","unstructured":"Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry. 2004;65:9\u201315.","journal-title":"J Clin Psychiatry"},{"key":"3351_CR67","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"3351_CR68","doi-asserted-by":"publisher","first-page":"D258","DOI":"10.1093\/nar\/gkh036","volume":"32","author":"Gene Ontology Consortium.","year":"2004","unstructured":"Gene Ontology Consortium. The gene ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32:D258\u201361.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR69","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199\u2013205.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-91","volume":"11","author":"A Martin","year":"2010","unstructured":"Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics. 2010;11:1\u20139.","journal-title":"BMC Bioinformatics"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03351-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T13:22:15Z","timestamp":1743945735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03351-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03351-1","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}